The first case of severe mpox has been reported in New York City, raising concerns about the potential for local transmission, though officials maintain the risk remains low.
The New York City Health Department has confirmed the first case of severe mpox, previously known as monkeypox, in a resident who recently traveled abroad. This case involves mpox clade I, one of the two primary genetic groups of the virus responsible for the illness.
Dr. Marc Siegel, a senior medical analyst for Fox News, explained that clade I is associated with more severe symptoms and can be life-threatening. “It spreads via direct contact or sex, and kissing, as well as through very close respiratory droplets, but not over longer distances by respiratory spread,” he noted.
Clade II, which caused a global outbreak in 2022, has a survival rate exceeding 99.9%, according to the Centers for Disease Control and Prevention (CDC). In contrast, clade I has been linked to more severe illness and fatalities, particularly during the 2024 outbreak in the Democratic Republic of the Congo and other parts of Africa.
The patient in New York City had traveled internationally, and health officials believe this case did not result from local transmission. “This appears to have come here from travel and has not spread locally,” Dr. Siegel remarked.
Despite the emergence of this severe case, NYC Health Commissioner Dr. Alister Martin reassured the public that there is currently no known local transmission of mpox clade I in the city. He emphasized that the risk for local residents remains low.
To mitigate the risk of mpox, the NYC Health Department recommends that individuals at risk receive and complete the two-dose vaccination series designed to prevent the disease. The CDC advises vaccination for men who are gay, bisexual, or have sex with men, who are 18 years or older, and who have other specific risk factors. Additionally, those planning to travel to regions where clade I mpox is prevalent should consider vaccination.
Individuals who have been in close contact with someone infected with mpox should seek vaccination within 14 days of exposure. As with many viral infections, those who are immunocompromised or very young face the highest risk of severe illness.
Experts note that vaccination can significantly reduce the likelihood of infection and lessen the severity of symptoms. The JYNNEOS vaccine, a two-dose regimen, is the most commonly recommended form of protection. Notably, individuals who have previously contracted mpox do not require vaccination.
Symptoms of mpox can include a painful, blistery rash on various parts of the body, fever, chills, exhaustion, muscle aches, headaches, swollen lymph nodes, and respiratory issues. These symptoms typically manifest one to three weeks following exposure.
In rare instances, mpox can lead to severe complications such as eye infections, painful skin lesions, and neurological problems. Treatment primarily involves supportive care to manage symptoms. In severe cases, patients may be prescribed TPOXX (tecovirimat), an antiviral medication used to treat infections related to smallpox, including mpox.
As health officials continue to monitor the situation, they urge the community to stay informed and take appropriate precautions. For more information on mpox and vaccination, residents are encouraged to consult local health resources.
According to Fox News, the situation remains under close observation by health authorities.